Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 12/29/2025

Management of HIV Infection in Pregnant Women

Antiretroviral Therapy

  • The American College of Obstetricians and Gynecologists recommends that all HIV-infected pregnant women should receive combination antiretroviral therapy (HAART) with at least 3 drugs throughout pregnancy, regardless of CD4 count or viral load, to prevent mother-to-child transmission and maintain maternal health 1, 2
  • Start or continue HAART immediately with a 3-drug regimen that includes zidovudine (ZDV) whenever possible, as ZDV remains the cornerstone of perinatal prevention even after 10 years of use 1
  • For women already on HAART when pregnancy is discovered, continue the current regimen unless it contains teratogenic agents like efavirenz, which must be discontinued immediately and replaced 1
  • If the woman requires treatment for her own health (CD4 <350/mm³ or AIDS-defining illness), antiretroviral drugs should not be stopped during the first trimester despite theoretical teratogenicity concerns 1
  • For women with HIV RNA >1000 copies/mL, combination HAART is mandatory; for those with <1000 copies/mL, either HAART or the 3-part PACTG 076 zidovudine regimen can be used 1

Critical First Trimester Considerations

  • Avoid efavirenz due to documented teratogenic potential (neural tube defects) 1
  • Avoid the combination of stavudine (d4T) plus didanosine (ddI) due to increased risk of lactic acidosis and hepatic steatosis in pregnant women 1
  • If discontinuation of all antiretrovirals is deemed necessary in the first trimester, stop all drugs simultaneously to prevent resistance, except when using drugs with long half-lives like nevirapine—in which case continue nucleoside analogues for 3-7 days after stopping the NNRTI 1

Monitoring Throughout Pregnancy

  • Measure viral load at baseline, monthly initially, then at 34-36 weeks gestation to guide delivery planning 2
  • Monitor CD4 counts to assess maternal immune status and need for opportunistic infection prophylaxis 3
  • Perform level II ultrasound for detailed fetal anatomic assessment, particularly if using combination therapy 3
  • Assess fetal growth and wellbeing during the third trimester with serial ultrasounds 3

Intrapartum Management

  • Continue HAART throughout labor and delivery—do not interrupt the regimen 1
  • Administer intravenous zidovudine during labor as part of the PACTG 076 protocol, even if the mother is on oral HAART 1
  • Offer scheduled cesarean section at 38 weeks gestation to women with viral loads >1000 copies/mL or unknown viral load, as this reduces transmission by approximately 50% 4
  • For women with undetectable or very low viral loads (<1000 copies/mL) on HAART, vaginal delivery is reasonable as the additional benefit of cesarean section is unclear in this population 4

Postpartum Management

  • Coordinate care between obstetricians and HIV specialists to ensure continuity of antiretroviral treatment 3, 5
  • For women who do not meet criteria for treatment in non-pregnant individuals (CD4 >350/mm³, no AIDS-defining illness), consider discontinuing therapy after delivery with all drugs stopped simultaneously 1
  • Exception for nevirapine-containing regimens: Continue dual nucleoside analogues for 3-7 days after stopping nevirapine to reduce resistance risk 1
  • Counsel extensively about adherence challenges in the postpartum period, as physical changes and demands of caring for a newborn significantly impair adherence 3, 5
  • Screen for postpartum depression, which interferes with adherence and is associated with virologic failure and resistance development 5

Infant Care

  • Administer zidovudine prophylaxis to the newborn starting within 6-12 hours of birth, continuing for 6 weeks at 4 mg/kg twice daily 6
  • Obtain baseline complete blood count before starting ZDV and repeat after completing the 6-week regimen (at 12 weeks of age if abnormal), as anemia is the primary complication 3, 5
  • For infants whose mothers received combination therapy, perform more intensive hematologic and chemistry monitoring during the first weeks of life 3, 5
  • Start Pneumocystis carinii pneumonia (PCP) prophylaxis at 6 weeks of age after completing ZDV prophylaxis 3, 5
  • Perform HIV virologic testing according to current standards, with repeat testing after completion of prophylaxis if initial tests are negative 3, 5
  • Instruct mothers not to breastfeed in settings where safe formula alternatives are available, as this eliminates postnatal transmission risk 2

Long-Term Follow-Up

  • Maintain long-term follow-up of HIV-exposed infants into adulthood due to theoretical concerns about carcinogenicity of nucleoside analogues 7, 8
  • Include yearly physical examinations for all antiretroviral-exposed children, with gynecologic evaluation and Pap smears for adolescent females 8
  • Document antiretroviral exposure in the child's permanent medical record, particularly for uninfected children 7, 8

Management of New‑Onset HIV During Pregnancy

Initiation of Antiretroviral Therapy

  • All pregnant women with a new HIV diagnosis should start a three‑drug combination antiretroviral regimen immediately, irrespective of CD4 count or viral load, to prevent mother‑to‑child transmission and protect maternal health. [9][10]
  • Initiating therapy without delay can reduce perinatal HIV transmission to less than 1 % when appropriate ART is used. [9][10]

Monitoring During Pregnancy

  • Baseline and monthly HIV viral load measurements (with an additional test at 34–36 weeks) are required to guide delivery planning. (Citation embedded in the above statements)
  • CD4‑cell counts should be monitored throughout pregnancy to assess maternal immune status and determine the need for opportunistic infection prophylaxis. 10

Delivery Planning Based on Viral Load

  • If the maternal viral load is <150 copies/mL at 34–36 weeks, vaginal delivery is recommended provided there are no obstetric contraindications. (CDC guideline) [11][12]
  • If the viral load is >1 000 copies/mL or unknown, a scheduled cesarean delivery at 38 weeks is advised, which reduces transmission by roughly 50 %. (CDC guideline) [11][12]
  • For viral loads between 150–1 000 copies/mL, cesarean delivery may be considered after clinical judgment. (CDC guideline) [11][12]

Post‑partum Maternal Management

  • Antiretroviral therapy should be continued after delivery to maintain maternal health; pregnancy alone is not a reason to stop treatment. (CDC guideline) [11][12]
  • Mothers should be counseled not to breastfeed when safe formula alternatives are available, as this eliminates the risk of post‑natal HIV transmission. (CDC guideline) [11][12]13

Infant Antiretroviral Prophylaxis & Diagnostic Testing

  • High‑risk newborns (e.g., maternal viral load > 1 000 copies/mL or no maternal ART) receive zidovudine prophylaxis starting within 6–12 hours of birth and continued for 6 weeks. (Guideline based on cited evidence)
  • HIV virologic testing (PCR for HIV DNA/RNA) should be performed at birth for high‑risk infants, then repeated at 2–4 weeks, 1–2 months, and 4–6 months. [9][10]
  • Any positive virologic result must be confirmed with an immediate repeat test. 10
  • Definitive exclusion of infection is achieved with negative PCR results at 1 month and 4 months plus a negative HIV antibody test at 12–18 months. [9][10]

Counseling, Support, and Legal/Social Services

  • Comprehensive HIV‑prevention counseling—including discussion of perinatal transmission risks and mitigation strategies—should be provided to all pregnant women with HIV. (CDC guideline) [14][11]
  • Assessment for potential negative psychosocial impacts (e.g., discrimination, domestic violence, mental health challenges) is recommended. (CDC guideline) [11][12]13
  • Referral to appropriate psychological, social, and legal services should be arranged as needed. (CDC guideline) [11][12]13
  • Nondirective counseling about future reproductive options should be offered. (CDC guideline) [11][12]13

Long‑Term Follow‑Up of HIV‑Exposed Infants

  • Families should be encouraged to test any subsequent children born after the mother’s HIV infection for HIV exposure. (CDC guideline) [11][13]

General Principles

  • Single‑ or dual‑drug regimens are not acceptable; combination ART with at least three agents must be used for all pregnant women with HIV. 9
  • Coordination between obstetric providers and HIV specialists is essential to manage drug interactions, side‑effects, and monitoring requirements. (CDC guideline) [11][12]

REFERENCES

2

HIV and Pregnancy [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

6

Nevirapine Prophylaxis for Infants Born to HIV-Infected Mothers [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025